advertisement
Abstract #26886 Published in IGR 12-3
IStent((registered trademark)): Trabecular micro-bypass stent for open-angle glaucoma
Traverso CE; Papadia M; Scotto R; Bagnis AExpert Review of Ophthalmology 2010; 5: 443-450
Glaucoma afflicts tens of millions worldwide and is a leading cause of irreversible blindness. The primary objective in managing glaucoma is the reduction of elevated intraocular pressure. Bypassing outflow resistance at the level of the trabecular meshwork can re-establish physiologic aqueous humor outflow from the anterior chamber, thus reducing intraocular pressure. The iStent((registered trademark)) trabecular micro-bypass stent is implanted directly into Schlemms canal through a clear corneal incision as a standalone procedure or in conjunction with cataract surgery to facilitate aqueous outflow through Schlemms canal. iStent is a minimally invasive alternative to current treatments for patients with open-angle glaucoma and has also been shown to offer distinct clinical advantages in the early stages of the disease.
C. E. Traverso. Centro di Ricerca Clinica e Laboratorio per Il Glaucoma e la Cornea, Clinica Oculistica Di.N.O.G., University of Genova, Genova, Italy. mc8620@mclink.it
Classification:
12.8.2 With tube implant or other drainage devices (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
